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Abstract
We have constructed a series of plasmids encoding premembrane (prM) and envelope (E) protein genes of dengue virus type 2 (DEN-2).
These plasmids included an authentic DEN-2 prM-E construct (pCBD2-14-6), and two chimeric constructs, 90% DEN-2 E-10% Japanese
encephalitis (JE) virus E (pCB9D2-1J-4-3) and 80% DEN-2 E-20% JE E (pCB8D2-2J-2-9-1). Monoclonal antibody (MAb) reactivity
indicated that all three plasmids expressed authentic DEN-2 virus E protein epitopes representative of flavivirus domains 1, 2, and 3.
However, only the pCB8D2-2J-2-9-1 construct secreted high levels of prM, M (membrane), and E proteins into the culture fluid of
plasmid-transformed COS-1 cells. The major portion of the prM and E proteins expressed by COS-1 cells transformed by pCBD2-14-6 or
pCB9D2-4-3 plasmids remained membrane-bound. The results supported the notion that an unidentified membrane retention sequence is
located between E-397 and E-436 of DEN-2 virus E protein. Replacing the carboxyl-terminal 20% of DEN-2 E (397-450) with the
corresponding JE sequence had no effect on anti-DEN-2 MAb reactivity, indicating that this region is antigenically inert, although it is
required for antigen secretion. Plasmid pCBD2-2J-2-9-1, which expressed secreted forms of prM/M and E that have the potential to form
subviral particles, was superior to other constructs in stimulating an antibody response. Ninety percent neutralization titers ranging from 1:40
to1:1000 were observed in seven of nine serum specimens from pCB8D2-2J-2-9-1-immunized mice. Eleven of twelve 2-day-old neonatal
mice, derived from a pCB8D2-2J-2-9-1 immunized female mouse, survived intraperitoneal challenge of DEN-2 New Guinea C virus.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
1Dengue (DEN) fever, an acute infection that occurs in
subtropical and tropical areas, is the most important arthro-
pod-borne viral disease of humans (Monath, 1994). DEN
viruses belong to the family of Flaviviridae, genus flavivi-
rus. There are four distinct DEN virus serotypes: DEN-1, -2,
-3, and -4. Infection with any of these viruses may be
asymptomatic, or cause a self-limited febrile illness known
as dengue fever (DF). In a small percentage of cases, how-
ever, infection results in a life-threatening dengue hemor-
rhagic fever or dengue shock syndrome (DHF/DSS). There
are approximately 100 million cases of DF occurring annu-
ally worldwide and an estimated 500,000 hospitalized DHF/
DSS reported. A safe and effective DEN vaccine is essential
to provide protection for all four virus serotypes in DEN
endemic and epidemic regions of the world. A live-attenu-
ated DEN vaccine has shown promising results in phase 1
clinical trials (Bhamarapravati and Sutee, 2000; Kanesa-
thasan et al., 2001). The reverse genetic technique using
infectious cDNA clones derived from yellow fever (YF)
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vaccine virus (17D), attenuated DEN-2 vaccine virus (PDK-
53), and genetically engineered, attenuated DEN-4
(814669) has greatly increased the potential of creating a
genetically engineered, live-attenuated chimeric DEN vac-
cine (Blaney et al., 2001; Guirakhoo et al., 2000; Huang et
al., 2000).
The use of DNA-based vaccines is a novel and prom-
ising immunization approach for the development of fla-
vivirus vaccines (Chang et al., 2001). Few of the flavi-
virus DNA vaccines have been evaluated in the
experimental animals other than mice. Candidate DNA
vaccine for Russian spring-summer encephalitis, Central
European encephalitis, and DEN-1 viruses have been
evaluated in nonhuman primates (Kochel et al., 2000;
Raviprakash et al., 2000; Schmaljohn et al., 1999). Jap-
anese encephalitis (JE) virus DNA vaccine was evaluated
in swine (Konishi et al. 2000b). Recently, we reported the
development of highly immunogenic, recombinant DNA
vaccines for JE and West Nile (WN) viruses that induced
protective immunity in mice following a single intramus-
cular (im) injection (Chang et al., 2000; Davis et al.,
2001). The recombinant WN virus construct also induced
protective immunity in horses following a single im in-
jection (Davis et al., 2001).
The protective immunity induced after DNA vaccination
may correlate with the ability of plasmid DNA to direct
synthesis of secreted premembrane/membrane (prM/M) and
envelope (E) proteins by the host cells. COS-1 cells trans-
formed with tick-borne encephalitis (TBE), JE or WN plas-
mids secreted the TBE, JE or WN prM/M and E proteins in
the form of extracellular subviral particles (EPs) into the
culture fluid (Allison et al., 1999; Davis et al., 2001; Hunt et
al., 2001). The highly immunogenic, noninfectious EPs
have potential not only as biosynthetic subunit vaccines but
also as serodiagnostic antigens to replace virus-infected
suckling mice brain preparations (Davis et al., 2001; Hunt et
al., 2001; Konishi and Fujii, 2002; Konishi et al., 1997,
2001). In the present study, we have identified a potential
membrane retention region between E-397 and E-436 of
DEN-2 virus E protein. Replacing DEN-2 virus E-436 to
E-450 with the corresponding E region of JE virus to con-
struct a chimeric plasmid containing 90% DEN-2 E and
10% JE E gene had only minor effect on the prM and E
secretion. However, the DEN-2-JE virus chimeric plasmid,
consisting of the transmembrane signal sequence of JE
virus, followed by prM and 80% E (E-1 to 397) of DEN-2,
and 20% E of JE virus (corresponding to DEN-2 E-397 to
E-450), secreted prM/M and E proteins efficiently in plas-
mid transformed COS-1 cells. The immune response in
mice after im immunization of DEN-2 plasmids correlated
with the efficiency of prM/M and E secretion. Only the
construct efficiently secreting prM/M and E antigens had
the capacity to stimulate high-titered neutralizing (Nt) an-
tibodies in plasmid-vaccinated mice.
Results
Transient expression of DEN-2 virus recombinant antigen
Expression of the prM and E genes of DEN-2 virus or a
chimeric E gene from a combination of DEN-2 and JE virus
sequences (80% DEN-20% JE or 90% DEN-10% JE) was
accomplished by separate transformations of each of the
three recombinant DEN-2 DNA plasmids into COS-1 cells.
The basic plasmid design was based on results from previ-
ous studies with JE virus and WN virus recombinant plas-
mids in which plasmid-transformed cells expressed and
secreted authentic viral proteins into the cell culture fluid
(Chang et al., 2000; Davis et al., 2001). Transient expres-
sion of DEN-2 recombinant proteins was initially assessed
by Ag-capture ELISA of cell-culture supernatants and by
immunofluorescence antibody assay (IFA) of acetone-fixed,
transformed COS-1 cells (Chang et al., 2000). The optimum
antigen expression was determined to be 48 h following
electroporation.
Epitope mapping of the E protein expressed by transiently
transformed COS-1 cells
The DEN-2 protein expressed by each of the recombi-
nant plasmids was evaluated by IFA using a panel of murine
monoclonal antibodies (MAbs) with known reactivity to
DEN-2 virus (Table 1) (Henchal et al., 1985; Roehrig et al.,
1998). The MAb panel included antibodies reactive with
each of the three antigenic domains of the E protein of
flaviviruses as well as prM and C proteins (Guirakhoo et al.,
1989; Rey et al., 1995). The MAbs specific for flavivirus
antigenic Domains 2 and 3 showed nearly identical quali-
tative reactivity with DEN-2 virus and each of the three
plasmid-expressed proteins. Domain 1 specific MAb
1B4C-2 also showed a similar reactivity pattern with all
expressed proteins. However, two of the Domain 1 specific
MAbs, 2B3A-1 and 9A4D-1, were much less reactive with
E protein expressed by plasmids pCBD2-14-6 and
pCB9D2-1J-4-3 as shown by endpoint titration (values in
parentheses, Table 1). Comparison of the endpoint titers
revealed the apparent poor expression of epitopes C3 and
C4 in constructs containing 100% DEN-2 E and 90%
DEN-2 E-10% JE E. MAb 2H2, specific for prM, had the
same reactivity with antigen expressed by all three plasmids.
Anti-C MAb 1A2A-1 reacted well with DEN-2 virus and had
low-level, nonspecific reactivity with the plasmid-expressed
viral proteins, which included prM and E, but not C.
Comparison of secreted protein and membrane-bound
protein produced by each of the three DEN-2
recombinant plasmids
Similar amounts of cell-culture fluid were harvested
from COS-1 cells 48 h posttransformation for each recom-
binant DEN-2 plasmid. The DEN-2 viral antigens secreted
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into untreated culture supernatants were first assessed by
Ag-capture ELISA (Table 2). The cells transformed with
100% DEN-2 E and 90% DEN-2 E-10% JE E plasmids did
not secrete DEN-2 viral antigens in replicate transformation
experiments, thus, were ELISA-negative in unconcentrated
culture supernatants. However, cells transformed with the
80% DEN-2 E-20% JE E plasmid secreted DEN-2 viral
antigens and demonstrated ELISA titers between 1:8 and
1:32 in different transformation experiments. To increase
the antigen concentration that may be undetectable by either
Ag-capture ELISA or Western blot, an equivalent volume of
the culture fluid from each plasmid was concentrated 100-
fold by polyethylene glycol (PEG) precipitation, followed
by ethanol extraction to remove PEG, which interfered with
subsequent analysis by polyacrylamide gel electrophoresis.
The relative amount of secreted antigen expressed by each
plasmid was determined by Ag-capture ELISA analysis of
both PEG-precipitated and ethanol-extracted cell-culture
Table 1
Characterization of DEN-2 E glycoprotein epitopes expressed by the recombinant DEN-2 plasmids as determined by the indirect immunofluorescence
antibody assay (IFA)
Antibody Controlsa Plasmid constructa
MAb (epitope)b Antigenic domainc PRNTd DEN-2-infected
cells
Normal
cells
pCBD2-14-6
(100D2-E)
pCB9D2-IJ-4-3
(90D2-E-10JE-E)
pCB8D2-2J-2-9-1
(80D2-E-20JE-E)
4G2 2 / 4 — 4 4 4
6B6C-1 (A1) 2 / 4 — 4 4 3–4
4E5 (A2) 2 Yes 3 — 3–4 3–4 2–3
1B7 (A5) 2 Yes 3–4 — 4 4 2–3
1B4C-2(C1) 1 No 3–4 (8000) — 2–3 (4000) 2–3 (4000) 2–3 (8000)
2B3A-1 (C3) 1 No 3–4 (3200) — 3 (100) 2 (100) 2–3 (3200)
9A4D-1 (C4) 1 No 3–4 — 2–3 (400) 1–3 (400) 3 (12800)
3H5 (B2) 3 Yes 4 — 4 4 4
10A4D-2 (B3) 3 Yes 2–3 — 3–4 3–4 2–3
1AID-2 (B4) 3 Yes 4 — 3–4 4 3–4
9D12-6 ? Yes 2–4 2–3 2–3 3–4
2H2 prM No 4 — 4 3–4 3–4
1A2A-1 Capsid No 2–3 — 1 2 1–2
a IFA substrates were acetone-fixed COS-1 cells, infected with DEN-2 16681, uninfected controls, or transformed with a DEN-2 recombinant plasmid.
b Monoclonal antibodies were used at a predetermined optimum dilution based on reactivity with DEN-2 16681 virus. For some MAbs, endpoint titers,
shown in parentheses, are reported and for others, only qualitative values are reported based on a scale from 1 to 4, with 3–4 considered positive, 2
equivocal, and 1 negative.
c Antigenic domains based on the E-glycoprotein of TBE virus (12, 30).
d Plaque-reduction neutralization activity at a 1:100 dilution of ascitic fluid, using a 90% plaque-reduction endpoint, except for 4G2 and 9D12-6, for which
a 50% neutralization endpoint is reported (14, 33).
Table 2
Detection of secreted and membrane-bound DEN-2 recombinant protein by antigen-capture ELISA
Plasmid Sample type Endpoint ELISA titer
pCBD2-14-6 (100D2-E) Culture fluid 1:1
PEG-precipitated culture fluida 1:10
PEG-precipitated, ethanol-extracted culture fluidb 1:20
Hydrophobic membrane protein preparationc 1:160
pCB9D2-1J-4-3 (90D2-E-10JE-E) Culture fluid 1:1
PEG-precipitated culture fluida 1:10
PEG-precipitated, ethanol-extracted culture fluidb 1:20
Hydrophobic membrane protein preparationc 1:80
pCB8D2-2J-2-9-1 (80D2-E-20JE-E) Culture fluid 1:8–1:32
PEG-precipitated culture fluida 1:640
PEG-precipitated, ethanol-extracted culture fluidb 1:80
Hydrophobic membrane protein preparationc 1:80
pEGFP Culture fluid 1:1
PEG-precipitated culture fluida 1:10
PEG-precipitated, ethanol-extracted culture fluidb 1:10
Hydrophobic membrane protein preparationc 1:10
a Culture supernatant from plasmid-transformed cells was precipitated with 10% polyethylene glycol (PEG) and resuspended in 1/100th of original volume.
b PEG-precipitated culture supernatant was extracted with 4% ethanol to remove PEG and the pellet was resuspended in 1/5 of the volume extracted.
c Hydrophobic membrane fractions were prepared as described under Materials and methods.
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fluid preparations (Table 2). Secreted antigen was detected
only from cells transformed with pCB8D2-2J-2-9-1, which
contained 80% DEN-2 E and 20% JE E genes. The recom-
binant plasmids containing either 100% DEN-2 E or 90%
DEN-2 E-10% JE E genes produced no ELISA-detectable
antigen in the culture fluid, despite efforts to concentrate
expressed protein.
Western blot analysis was also used to evaluate the
production of secreted antigen by each of the DEN-2 re-
combinant plasmids. For comparison purposes, equivalent
volumes of PEG-precipitated, ethanol-extracted cell-culture
supernatant were run on NuPAGE gradient gels, electro-
blotted to nitrocellulose, and analyzed using MAbs or poly-
clonal antisera capable of reacting with all DEN-2 structural
proteins (Fig. 1A). Western blot analysis showed greater
sensitivity in detecting recombinant antigen than Ag-cap-
ture ELISA since DEN-2-specific proteins were detected in
the culture fluid from two of the plasmids, pCB8D2-2J-2-
9-1 and pCB9D2-1J-4-3. Plasmid pCB8D2-2J-2-9-1 ex-
pressed the greatest amount of secreted antigen which was
shown to be composed of E, prM, and M proteins. The
amount of M protein seemed to be variable for replicate
transformations, perhaps due to varying efficiency of prM
processing (data not shown). Relatively less secreted
antigen was produced by pCB9D2-1J-4-3, and barely
detectable levels were found for the pCBD2-14-6 prepa-
ration, which appeared to contain relatively less ex-
pressed E protein, especially if the nonspecific reactivity
of the E-specific MAb, 1A6A-8, on the control pEGFP
was taken into consideration (Fig. 1A, lanes a, b for 14-6
and GFP).
Since E, prM, and M are membrane-associated proteins
throughout their intracellular synthesis, any assessment of
the expression of these proteins by the three recombinant
DEN-2 plasmids should include an evaluation of cell-mem-
brane preparations from plasmid-transformed cells. The
Mem-PER Mammalian Membrane Protein Extraction Re-
agent Kit (Pierce, Rockford, IL) was used to isolate the
integral membrane proteins from equivalent numbers of
transformed cells for each recombinant plasmid. Hydropho-
bic proteins were separated from hydrophilic proteins by
phase partitioning. Preliminary analysis by Ag-capture
ELISA indicated that the hydrophilic protein fraction was
nonreactive (data not shown); however, the hydrophobic
protein fractions from COS-1 cells transformed with each of
the recombinant DEN-2 plasmids had similar titers in
ELISA tests (Table 2). These results indicated that recom-
binant antigen was expressed by all three plasmids follow-
ing transformation, but was not always secreted.
Confirmation of the ELISA results for the hydrophobic
Fig. 1. Comparison of secreted and membrane-bound recombinant protein by Western blot. (A) Analysis of secreted recombinant antigen following
PEG-precipitation and ethanol extraction of culture fluid for DEN-2 plasmids pCB8D2-2J-2-9-1 (80D2E), pCB9D2-1J-4-3 (90D2E), and pCBD2-14-6
(100D2E), and control plasmid pEGFP. Lane 1 (V), purified DEN-2 virus stained by Gold Blot (Owl Separation Systems, Portsmouth, NH). Reactivity of
secreted, recombinant antigen from each plasmid with (a), anti-envelope (E) specific MAb 1A6A-8; (b), a mixture of MAb 1A6A-8, anticapsid (C) specific
MAb 1A2A-1, antiserum specific for a DEN-2 virus membrane (M) protein peptide (M protein aa 1-34), and antiserum specific for DEN-2 virus premembrane
(prM) protein; and (c), normal mouse ascites. (B) Analysis of recombinant plasmid-transformed cell hydrophobic membrane proteins. Lane 1 (V), purified
DEN-2 virus stained by Gold Blot; Lane 2 (V), reactivity of purified DEN-2 virus with a mixture of MAb 1A6A-8, MAb 1A2A-1, antiserum specific for
DEN-2 virus M protein, and antiserum for DEN-2 virus prM protein. Reactivity of isolated hydrophobic membrane proteins from each plasmid-transformed
cell line with (a), MAb 1A6A-8; (b), a mixture of MAb 1A6A-8, MAb 1A2A-1, antiserum specific for DEN-2 virus M protein, and antiserum for DEN-2
virus prM protein; and (c), normal mouse ascites.
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protein fractions was accomplished by Western blot (Fig.
1B). Equivalent volumes of hydrophobic protein frac-
tions from each of the plasmid-transformed cells were di-
luted according to the manufacturer’s recommendations for
SDS–polyacrylamide gel electrophoresis to reduce band and
lane distortion. Immunoblotting with E-, prM-, C-, and
M-specific MAbs or polyclonal antisera showed that all
three recombinant DEN-2 plasmids produced similar
amounts of recombinant antigen composed of E and prM.
No M protein was detected, either because it was not pro-
cessed from prM or because the levels were too low to be
detected. Despite efforts to reduce band distortion, high
levels of detergent in the hydrophobic protein samples ap-
parently caused E and prM to run in a slightly aberrant
manner (slower migration) compared to samples without
such high concentrations of detergents (compare E and prM
migration in Figs. 1A and 1B).
Comparison of the immune response in mice vaccinated
with three different DEN-2 recombinant DNA plasmids
To compare the extent and functionality of antibody
responses stimulated by DNA vaccination, 3-week-old ICR
mice were immunized by im injection with 100 g of either
pCB8D2-2J-2-9-1, pCB9D2-1J-4-3, pCBD2-14-6, or
pEGFP on weeks 0 and 3. Outbred mice were selected for
this study to provide the genetic heterogeneity expected in
nonhuman primates planned for future study. Mice were
bled 3, 6, and 9 weeks after the primary immunization.
Individual and pooled sera were tested by indirect ELISA,
using screening dilutions of 1:100 and 1:400 at 3 and 6
weeks postvaccination and endpoint titrations at 9 weeks
postvaccination. Nine-week sera were also tested by plaque
reduction neutralization test (PRNT) with both DEN-2 and
JE viruses. The ELISA results showed that after one immu-
Table 3
Immunogenicity of three DEN-2 recombinant plasmids in ICR mice
Plasmid DNAb Mouse No. ELISA on DEN-2 virus PRNT on
DEN-2 virusa
Endpoint titer
9 wks, p.v.
PRNT on JE
virusa
Endpoint titer
9 wks, p.v.
Screen 3 wks,
p.v.c
Screen 6 wks,
p.v.c
Endpoint titer
9 wks, p.v.
1:100 1:400 1:100 1:400
pCB8D2-2J-2-9-1
(80D2-E-20JE-E)
Pool, 1,2,4–10 NDd ND   64,000 ND ND
1     64,000 1000 2
2     32,000 1000 2
4     16,000 200 2
5     4000 10 2
6     16,000 200 2
7     64,000 100 2
8     8000 40 2
9     6400 2 4
10     64,000 1000 2
pCB9D2-IJ-4-3
(90D2-E-10JE-E)
Pool, 1–10 ND ND   1000 ND 2e
1     400 10 ND
2     200 10 ND
3     4000 2 4
4     200 10 ND
5     400 10 ND
6     4000 2 2
7  /   100 10 ND
8     200 10 ND
9     4000 2 2
10     4000 2 2
pCBD2-14-6
(100D2-E)
Pool, 1–10 ND ND   200 2f 2g
1     400 10 ND
2,3,6–9     100 ND ND
4     1000 2 2
5     2000 8 2
10     100 ND ND
PEGFP Pool, 1–10  ND  ND 100 2 2
a PRNT, plaque-reduction neutralization test, 90% neutralization endpoint.
b Mice were immunized intramuscularly with 100 g plasmid DNA on weeks 0 and 3.
c ELISA screens used sera diluted 1:100 and 1:400.
d ND, not done.
e Pool, 1, 2, 4, 5, 7, 8.
f Pool, 2, 3, 6–10.
g Pool, 1–3, 6–10.
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nization (3-week sera) all mice given pCB8D2-2J-2-9-1 had
seroconverted, whereas only 50% of pCB9D2-1J-4-3- and
20% of pCBD2-14-6-vaccinated mice reacted with DEN-2
virus (Table 3). By 9 weeks postvaccination, all mice vac-
cinated with either pCB8D2-2J-2-9-1 or pCB9D2-1J-4-3
demonstrated anti-DEN-2 ELISA reactivity; however, the
geometric mean titers were significantly different, 1:20,000
vs 1:708, respectively. Only 40% of pCBD2-14-6-immu-
nized mice had anti-DEN-2 ELISA titers greater than 1:100.
A Western blot of pooled 9-week sera from pCB8D2-2J-2-
9-1-immunized mice on purified DEN-2 virus showed that
the immunodominant response was to the E glycoprotein,
with only slight reactivity detected to prM and M (data not
shown).
An even more significant result in terms of evaluating the
vaccine potential of the three DEN-2 plasmids was the
induction of virus-Nt antibody in seven of nine mice im-
munized with pCB8D2-2J-2-9-1. The titers reported are
based on a 90% plaque-reduction endpoint (Table 3); how-
ever, if a 70 or 50% neutralization endpoint is used, nine of
nine sera have PRNT titers of 1:2 or 1:40, respectively
(data not shown). Ninety percent neutralization titers ranged
from 1:40 to 1:1000 for the seven sera with Nt activity.
None of the mice immunized with pCB9D2–1J-4-3 pro-
duced Nt antibody, and only 1 of 10 sera from pCBD2-14-
6-vaccinated mice neutralized virus, but at a titer of only
1:8. We did not challenge these vaccinated mice with
DEN-2 virus since 12-week-old ICR mice are resistant to
DEN-2 virus challenge by either intraperitoneal (ip) or in-
tracranial route. For the purpose of comparison, mice chal-
lenged with DEN-2 New Guinea C strain by the ip route had
a mean neutralization titer of 1:10 (Konishi et al., 2000a).
Since two of the recombinant plasmids contained JE
virus E-gene sequences, all sera were evaluated for JE virus
Nt activity; however, no activity was detected at the 90%
neutralization endpoint for mice in any of the immunization
groups. Mice immunized with the control plasmid pEGFP
showed no reactivity to either DEN-2 or JE viruses.
Passive protection of neonatal mice derived from
pCB8D2-2J-2-9-1-vaccinated female
Female ICR mice were vaccinated with one dose of 100
g/100 l of pCB8D2-2J-2-9-1 plasmid DNA at the age of
3 weeks. For evaluation of passive protection by maternal
antibody, pups were obtained from a female that had Nt titer
of 1:160 at 9-weeks postvaccination. Pups were challenged
ip at 2 days after birth with 50,000 PFU/50 l of NGC virus.
Pups from an unvaccinated female, challenged at 1 day after
birth with 50,000 PFU/50 l of NGC virus, were used as
unvaccinated controls. Eleven of 12 pups nursed by the
vaccinated mother (PRNT titer of 1:160) survived viral
infection, whereas none of 12 pups, receiving 50,000 PFU
virus, from the control mother survived. Limited DEN-2
virus replication occurred in the survived pups since DEN-2
ELISA antibody (1:100) was detected in the serum of all
survived pups at 25 days postchallenge.
Discussion
The use of plasmid vectors to express prM/M and E
proteins that are able to stimulate a protective immune
response is a novel and promising approach for the devel-
opment of flavivirus vaccines (Chang et al., 2001). It is also
an important step toward the development of a stably trans-
formed cell line that constitutively produces and secretes
noninfectious subviral particles as the potential source of a
biosynthetic subunit vaccine and serodiagnostic antigen.
Vaccination with the recombinant plasmid results in endog-
enous expression of prM and E proteins and stimulates
anti-prM and E antibody responses in the host. We have
designed a recombinant eukaryotic expression plasmid that
contains optimized transcriptional and translational ele-
ments that enhanced the expression and secretion of JE and
WN virus prM/M and E proteins into the culture medium of
transiently transformed cells (Chang et al., 2000; Davis et
al., 2001). Initially, the same strategy was applied to con-
struct a recombinant DEN-2 plasmid, pCBD2-14-6, consist-
ing of the authentic DEN-2 prM and E gene regions. Anti-
genic mapping of DEN-2 proteins expressed by the
transformed COS-1 cells indicated that the prM and E
proteins had a similar fluorescence intensity and MAb re-
activity compared to virus-infected cells (Table 1). How-
ever, the staining pattern observed with plasmid-trans-
formed cells was a globular pattern of intensely stained,
large inclusion bodies as compared to the virus-infected
cells, which showed a more evenly dispersed or diffused
staining pattern.
Surprisingly, these pCBD2-14-6-transformed COS-1
cells failed to secrete a DEN-2 antigen detectable by Ag-
capture ELISA, and plasmid vaccination failed to stimulate
anti-DEN-2 virus Nt antibody in im immunized mice (Table
3). Studies with recombinant vaccinia viruses expressing
C-terminally truncated E proteins suggested that the first
392 amino acids of the DEN-4 virus E sequence are critical
in maintaining proper antigenic structure of the E protein
and that the C-terminal 20% of DEN-4 E contains a mem-
brane retention signal (Men et al. 1991). A similar mem-
brane retention signal may also present in the C-terminal
region of DEN-2 E and could have caused an intracellular
accumulation of viral protein and a resultant pattern of
globular fluorescent staining in the pCBD2-14-6-trans-
formed, acetone-fixed cells. This IFA staining pattern was
not observed in the JE or WN recombinant plasmid-trans-
formed cells (Chang et al., 2000; Davis et al., 2001). We,
therefore, constructed two additional plasmids, pCB9D2-1J-
4-3 and pCB8D2-2J-2-9-1, for which 10 or 20% of the
C-terminal DEN-2 E was replaced with the corresponding
region of JE virus E protein. The pCB9D2-1J-4-3 plasmid
secreted very low levels of prM and E proteins, detectable
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only by Western blot in transiently transformed COS-1
cells; only pCB8D2-2J-2-9-1-transformed cells secreted
DEN-2 virus prM/M and E proteins that could be detected
both by Ag-ELISA and Western blot (Fig. 1 and Table 2).
Particle assembly and secretion is influenced by prM and
E interaction. Studies on TBE virus have indicated that
interactions between prM and the ectodomain of E are
involved in prM-mediated intracellular transport of prM-E
heterodimers. Interactions between prM and both a pre-
dicted stem region (H2) and a first transmembrane region
(TM1) of E are factors stabilizing the prM-E interaction,
presumably leading to particle formation (Allison et al.,
1999). Replacement of the C-terminal 20% of DEN-2 E
with the corresponding JE E sequence to construct
pCB8D2-2J-2-9-1 resulted in DEN-2 prM and chimeric E
secretion, most likely in a particulate form [based on the
immunogenic quality of this antigen (Table 3)]. The major
portion of the prM and E proteins expressed by pCBD2-
14-6- and pCB9D2-4-3-transformed COS-1 cells remained
membrane-bound (Table 2 and Fig. 1). This result substan-
tiated the observation that a membrane retention sequence,
similar to an unidentified sequence in DEN-4 virus E, is also
present in the C-terminal stem region of the DEN-2 E
protein. It also provided evidence that H2 and TM1 of JE E
could interact with DEN-2 prM, perhaps stabilizing the
prM-E interaction leading to prM/M and E protein secre-
tion. The prM processing resulted in M protein-containing
virion occurs at the latest stage during flavivirus maturation.
The prM protein is essential for maintaining proper con-
formation and secretion of the E protein during prM-E
maturation (Aberle et al., 1999; Allison et al., 1995). For
Murray Valley encephalitis virus, the ectodomain of E pro-
tein interacting with prM has been estimated to be between
amino acids 200 and 327 (Guirakhoo et al., 1992). Recom-
binant vaccinia viruses expressing C-terminally truncated E
proteins suggest that the first 392 amino acids of the DEN-4
virus E sequence is required for proper antigenic structure
(Men et al., 1991). We believe that proper prM and E
interactions as well as the structural integrity of E are
maintained in the protein expressed by all three DEN-2
constructs. Replacement of the C-terminal 20% of E in
pCB8D2-2J-2-9-1, conserving 397 amino acids of authentic
DEN-2 E, was expected to have a minimum effect on the
antigenic structure of E and to preserve prM-E interactions.
Interactions of the prM and stem-anchor region of E are not
virus-species specific. Replacing the stem-anchor region of
DEN-2 E with the corresponding JE sequence had no effect
on MAb reactivity (Table 1), indicating that this region is
antigenically inert, but is required for prM/M and E secre-
tion, and possibly assembly of prM/M-E containing EPs.
The plasmid construct responsible for secreting EPs of
TBE virus prM and E protein was superior to constructs
producing primarily intracellular or soluble forms of E pro-
tein in terms of extent and functionality of the antibody
response (Aberle et al., 1999). Here we demonstrated that
the ability of DEN-2 plasmid DNA to stimulate Nt antibody
was correlated with the secretion of prM/M and E (Fig. 1,
Tables 2 and 3). The morphology and physical character of
secreted prM and E were not investigated in this study. It is
likely that prM/M and E secreted by the pCB8D2-2J-2-9-1
construct forms EPs, which represent a potent immunogen
with multiple, protective antigens presented on the particle
surface.
Previous attempts to develop a DEN-2 virus DNA vac-
cine has resulted in various degrees of success (Kochel et
al., 1997; Konishi et al., 2000a; Simmons et al., 2001).
Vector components in those studies are similar to the
present study, in which RNA transcripts of the DEN insert
are regulated by the cytomegalovirus early gene promoter
and bovine growth hormone poly(A) termination signal.
However, the Nt-inducing efficiency of DNA vaccine in
mice is significantly higher in our study than previous re-
ports. Of the prM and E gene regions reported in the pre-
vious publications, one construct is similar to our 100%
DEN-2 plasmid (Konishi et al., 2000a), and the other con-
tains only 91% of the E gene (Kochel et al., 1997). Kozak’s
consensus sequence used in our construct could enhance the
translation efficiency of the DEN-2 insert (Chang et al.,
2000). The transmembrane signal peptide sequence (derived
from JE virus) used in our construct has improved cleavage
probability and could influence the proper translocation as
well as processing of prM/M and E proteins. Signal peptide
differences in various constructs may account for the dif-
ference in protein translocation, cleavage site presentation,
and correct topology of prM and E proteins (Chang et al.,
2001). However, it is highly probable that the higher Nt-
inducing efficiency of the 80% DEN-2 E construct in mice
in the present study is due to the synergistic effects of
transcriptional and translational elements that increase both
the secretability and the particle formation of DEN-2 prM
and E proteins. Coimmunization of the immunostimulatory
CpG motif-containing pUC19 plasmid, including plasmid-
expressing murine GM-CSF in the vaccine regimen, or
replacing the C-terminal 43 amino acids of E with lyso-
some-associated membrane retention sequence, improved
the antibody response to the DEN-2 vaccine (Porter et al.,
1998; Raviprakash et al., 2001).
Age-dependent resistance to viral infection in outbred
mice has been observed in flaviviruses, including four se-
rotypes of DEN, YF, St. Louis encephalitis, and JE viruses.
The development of a consistent challenge protocol to ad-
dress protective efficacy is essential for future multivalent
DNA vaccine trials in mice. Previously, we observed that
maternal antibodies could provide passive protection in neo-
natal mice from JE virus induced encephalitis by ip chal-
lenge (Chang et al., 2000). The protective efficacy in the
baby correlated with the mother’s serum Nt antibody titer. A
similar strategy of immunizing female mice with the 80%
DEN-2 E-20% JE E construct indicated that, indeed, ma-
ternal antibody capable of Nt DEN-2 virus could also pro-
vide passive protection in neonatal mice from DEN-2 virus
ip challenge. Thus, enhancement of the vaccine potential of
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flavivirus DNA can be achieved by manipulation of an
expression plasmid for enhancing transcription and transla-
tion, promoting correct polyprotein processing and assem-
bly, and targeting prM/M and E proteins for secretion.
We have constructed recombinant plasmids which se-
crete prM and E proteins for DEN-1 and DEN-3, similar to
the 80% DEN-2 E construct in this study (G. J. Chang,
unpublished results). We have also established DEN-1, -2,
and -3 plasmid-transformed cell lines that constitutively
express and secrete prM/M and E proteins for these three
viruses. Objectives of an ongoing study are to obtain both
DEN-4 and YF plasmid constructs and to establish DEN-4
and YF prM/M and E antigen-producing cell lines. Using
candidate DNA vaccines for the four DEN serotypes, YF,
JE, and WN viruses, a future study will address the vaccine
potential of the formulated combination vaccine cocktails,
based on the disease prevalence in different geographic
regions. Noninfectious prM/M and E antigen-producing cell
lines can provide biosynthetic subunit vaccines as well as
standardized, noninfectious serodiagnostic antigens.
Materials and methods
Cell culture and virus strain
COS-1 cells (ATCC, Manassas, VA; 1650-CRL) were
grown at 37°C with 5% CO2 in Dulbecco’s modified Ea-
gle’s minimal essential medium (DMEM, GIBCO, Grand
Island, NY) supplemented with 10% heat-inactivated fetal
bovine serum (FBS, Hyclone Laboratories, Inc., Logan,
UT), 1 mM sodium pyruvate, 0.1 mM nonessential amino
acids, 20 ml/l 7.5% NaHCO3, 100 U/ml penicillin, and 100
g/ml streptomycin. Vero and C6/36 cells were grown
under the same conditions used for COS-1 cells. DEN-2
virus strain-16681 was used for cDNA cloning, IgG ELISA,
and the PRNT. Virus was propagated in C6/36 cell culture.
Virus used for immunological or biochemical studies was
purified by precipitation with 7% polyethylene glycol
(PEG-8000; Fisher Scientific, Fair Lawn, NJ), followed by
ultracentrifugation on 30% glycerol–45% potassium tartrate
gradients (Obijeski et al., 1976).
Mouse brain adapted DEN-2 New Guinea C strain virus
was used in the passive challenge experiment. This strain
was propagated in suckling mouse by intracranial injection,
and a 10% suspension of homogenized mouse brain was
used for the challenge study.
Plasmid construction
Genomic RNA was extracted from 150 l C6/36 cell-
culture medium infected with DEN-2 (16681) using the
QIAamp Viral RNA Kit (Qiagen, Santa Clarita, CA). Ex-
tracted RNA, resuspended in 80 l DEPC (Sigma, St.
Louis, MO), was used as a template in a reverse transcrip-
tase-PCR (RT-PCR) for the amplification of DEN-2 virus
prM/M and E genes. Primer sequences (Table 4) were
designed based on the published sequence (Kinney et al.,
1997). Restriction enzyme site KasI was incorporated at the
5-terminus of the cDNA amplicon. An in-frame termina-
tion codon, followed by a NotI restriction site, was intro-
duced at the 3-terminus of the cDNA amplicon. The
DEN-2 virus cDNA amplicon was digested with KasI and
NotI enzymes and inserted into the KasI and NotI sites of a
pCBJESS vector to form the 100% DEN-2 E plasmid,
pCBD2-14-6. The pCBJESS vector was derived from the
pCBamp plasmid which contained the cytomegalovirus
Table 4
Oligonucleotides used to construct DEN-2 virus prM-E expression plasmids, and the junction region of chimeric DEN-2 and JE E indicated
100% DEN-2-prM-E:
D2KasI-438a 5 TGTGCAGGCGCCTTCCATTTAACCACACGTAACG
CD2NotI-2402 5 TCGAGCGGCCGCTTCAACTAATTAGGCCTGCACCATGACTC
90% DEN-2-E & 10% JE-E:
T7 5CTTATCGAAATTAATACGACTCACTATAGG
CD2BstXI-2244 5ATAGATTGCTCCAAACACTTGGTGG
JE-2281 5 ACTCCATAGGAAAAGCCGTTCACC
CSP6 5 GCGAGCTCTAGCATTTAGGTGACACTATAG
DEN-24 3JE
90–10 Junction: Leu His Gln Val Phe Gly Gly Ala Phe Arg Thr
CTC CAC CAA GTG TTT GGT GGT GCC TTC AGA ACA
80% DEN-2-E & 20% JE-E:
T7 5 CTTATCGAAATTAATACGACTCACTATAGG
CD2BsmBI-2097 5 GAATTCGTCTCACTTCCTTTCTTAAACCAGTTGAGCTTC
JEBsmBI-2175 5 GGAATTCGTCTCGGAAGCACGCTGGGCAAGG
CSP6 5 GCGAGCTCTAGCATTTAGGTGACACTATAG 3
DEN-24 3JE
80–20 Junction: Asn Trp Lys Lys Gly Ser Thr Leu Gly Lys Ala
AAC TGG TTT AAG AAA GGA AGC ACG CTG GGC GCC
a Restriction enzyme sites encoded in oligonucleotides were highlighted by bold, italics, and underlined functions.
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early gene promoter, translational control element, and en-
gineered JE signal sequence element (Davis et al., 2001).
To construct the 90 and 80% DEN-2 E plasmids, the
100% DEN-2 plasmid, pCBD2-14-6, and the JE plasmid,
pCBJE1-14, were used as the PCR templates to amplify
DEN-2 and JE DNA sequence, respectively (Chang et al.,
2000). Primer sets to obtain the DEN-2 and JE gene frag-
ments are listed in Table 4. T7 and SP6 priming sites are
found in the pCBamp plasmid, derived from original
pcDNA-3 plasmid (Invitrogen, Carlsbad, CA). PCR-ampli-
fied DNA fragments for the 90% DEN-2-10% JE E gene
were digested with BstXI restriction endonuclease, ligated
with T4 DNA ligase, digested with KasI and NotI enzymes,
and inserted into the KasI and NotI sites of the pCBJESS
vector to obtain the plasmid pCB9D2-1J-4-3. PCR-ampli-
fied DNA fragments for the 80% DEN-2-20% JE E gene
were digested with BsmBI, ligated with T4 DNA ligase,
digested with KasI and NotI enzymes, and inserted into the
KasI and NotI sites of the pCBJESS vector to obtain the
plasmid pCB8D2-2J-2-9-1. Schematic representations of
the three plasmid constructs are shown in Fig. 2. The 90%
DEN-2-10% JE E and the 80% DEN-2-20% JE E junction
regions are shown in Table 4.
Automated DNA sequencing was performed on an ABI
Prism 377 Sequencer (Applied Biosystems/Perkin–Elmer,
Foster City, CA) according to the manufacturer’s recom-
mended procedures. The recombinant plasmids that had
correct prM and E sequences were identified.
Transient expression of DEN-2 recombinant antigen in
COS-1 cells by electroporation
COS-1 cells were electroporated separately with each
DEN-2 plasmid or green fluorescent protein expression
plasmid control (pEGFP, Clontech, San Francisco, CA)
using the protocol described previously (Chang et al.,
2000). Electroporated cells were seeded onto 75-cm2 culture
flasks and incubated at 37°C with 5% CO2. Six hours
following electroporation, the growth medium was replaced
with a maintenance medium containing 2% fetal bovine
serum. Tissue-culture medium and cells were harvested
separately 48 h following electroporation for antigen char-
acterization.
Epitope mapping using DEN-2 E-specific monoclonal
antibodies
Forty-eight hours following electroporation, adherent
cells were trypsinized, resuspended in phosphate-buffered
saline solution (PBS) containing 5% goat serum, spotted on
a 12-well spot-slide, and air dried. Cells adhered to the
spot-slide were fixed with acetone for 10 min at 20°C and
allowed to air dry. E-protein-specific monoclonal antibodies
were used to detect protein expression by the indirect IFA,
as described previously (Chang et al., 2000).
Characterization of the recombinant DEN-2 virus antigen
Tissue-culture medium was harvested 48 h following
electroporation. Antigen-capture (Ag-capture) ELISA was
used to detect secreted DEN-2 virus antigen in the culture
medium of transiently transformed COS-1 cells. MAb 4G2
and horseradish peroxidase conjugated MAb 6B6C-1 were
used to capture the DEN virus antigens and detect captured
antigen, respectively (Chang et al., 2000; Hunt et al., 2001).
Recombinant antigen in the medium was concentrated by
precipitation with 10% PEG-8000. The precipitant was re-
suspended in TNE buffer (50 mM Tris, 100 mM NaCl, 10
mM EDTA, pH 7.5) to 1/100th of the original volume,
clarified by centrifugation, and stored at 4°C. Recombinant
antigen concentrated by PEG precipitation and resuspended
in TNE buffer was extracted with 4% ethanol to remove
residual PEG (Hunt et al., 2001). Ethanol-extracted anti-
gens, hydrophobic membrane proteins from the transformed
cells, and gradient-purified DEN-2 virions were analyzed
under non-denaturing conditions on a NuPAGE, 4-12%
Bis–Tris gradient gel in an Excel Plus Electrophoresis Ap-
paratus (Invitrogen Corp.), followed by electroblotting onto
nitrocellulose membranes using a Excel Plus Blot Unit
(Invitrogen Corp.). DEN-2 virus-specific protein was de-
tected by Western blot using DEN-2 virus-specific MAbs
1A6A-8 (E-specific) and 1A2A-1 (capsid-specific), as well
as rabbit antiserum-specific for DEN-2 prM and mouse
Fig. 2. Schematic representations of plasmid vectors pCBD2-14-6 (100% DEN2-E), PCB9D2-1J-4-3 (90% DEN2-E-10% JE-E), and pCB8D2-2J-2-9-1 (80%
DEN2-E-20% JE-E). These plasmids include the human cytomegalovirus (CMV) early gene promoter, JE virus signal sequence, DEN-2 virus prM and E
gene region (amino-terminal 100, 90, or 80%), JE virus E gene region (carboxyl-terminal 10 or 20%), and bovine growth hormone poly(A) signal (BGH).
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serum-specific for a peptide composed of amino acids 1-34
of the DEN-2 M protein, and normal mouse ascitic fluid as
a negative control (Murray et al., 1993, Roehrig et al.,
1998).
Forty-eight hours following electroporation, transformed
cells for each plasmid were trypsinized and aliquots con-
taining 5  106 cells were resuspended in PBS. These cell
samples were processed for membrane protein extraction
using the Mem-PER Mammalian Membrane Protein Extrac-
tion Reagent Kit (Pierce) following the manufacturer’s pro-
tocol. Both hydrophobic and hydrophilic proteins were iso-
lated. This procedure was developed for enrichment of
integral membrane protein found in the hydrophobic phase.
Both hydrophobic and hydrophilic fractions were analyzed
by Ag-capture ELISA for DEN-2 recombinant antigen; the
hydrophobic fraction was also examined by Western blot as
described above.
Mouse vaccination and challenge
Groups of 10 three-week-old female ICR outbred mice
were used in the study. Mice were injected im with
pCBD2-14-6, pCB9D2-1J-4-3, pCB8D2-2J-2-9-1, or
pEGFP on weeks 0 and 3 with a dose of 100 g in a
volume of 100 l per mouse. The plasmid DNA was
purified from XL-1 blue cells with EndoFree Plasmid
Giga Kits (Qiagen) and resuspended in PBS, pH 7.5, at a
concentration of 1.0 g/l. Mice that received 100 g
pEGFP were used as plasmid-vaccinated controls. Mice
were bled every 3 weeks following injection, and the
DEN-2 virus-specific antibody response was evaluated by
indirect ELISA and PRNT.
For evaluation of passive protection by maternal anti-
body, pups were obtained from mating of nonimmunized
males with immunized females 9 weeks following a single
vaccination of pCB8D2-2J-2-9-1 (100 g/100 l in PBS) at
3 weeks of age. Pups from unvaccinated females were used
as the challenge control. Pups were challenged, ip, at 0 to 2
days after birth with 50,000 PFU/50 l of NGC virus and
observed daily for 3 weeks. Postchallenge serum was col-
lected from mice that survived challenge and was screened
by the IgG-ELISA at 1:100 and 1:400.
Serological tests
Pre- and postvaccination serum specimens were tested
for antibody binding ability to purified DEN-2 virus by
ELISA, for Nt antibody by PRNT, and for antibodies that
recognize purified DEN-2 virus proteins by Western blot-
ting. PRNT was performed with Vero cells, as previously
described (Chang et al., 2000), using DEN-2 (16681) and JE
(Nakayama) viruses. Endpoints were determined at a 90%
plaque-reduction level.
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